SPOTLIGHT: Novexel licenses anti-fungal drug


Novexel has agreed to license Indevus anti-fungal drug aminocandin for $1.5 million up front, $2.5 million on initiation of mid-level trials and up to $41 million in milestones and royalties. Release

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.